119 filings
8-K
CARA
Cara Therapeutics Inc
18 Jun 24
Cost Associated with Exit or Disposal Activities
4:16pm
8-K
CARA
Cara Therapeutics Inc
12 Jun 24
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
5:12pm
8-K
CARA
Cara Therapeutics Inc
7 Jun 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
CARA
Cara Therapeutics Inc
13 May 24
Cara Therapeutics Reports First Quarter 2024 Financial Results
4:10pm
8-K
CARA
Cara Therapeutics Inc
22 Mar 24
Departure of Directors or Certain Officers
4:05pm
8-K
7m2drpj8o4m qc
4 Mar 24
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
4:10pm
8-K
1hzkzdq0u0xsd4x
2 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:59pm
8-K
qbnfta 6jyt6fc8zgt
22 Jan 24
Cost Associated with Exit or Disposal Activities
4:19pm
8-K
ol4rs0 mc
18 Dec 23
Regulation FD Disclosure
7:10am
8-K
ze2vi0t
13 Nov 23
Corporate Presentation November 2023
4:28pm
8-K
azst0yz
13 Nov 23
Cara Therapeutics Reports Third Quarter 2023 Financial Results
4:11pm
8-K
rj2 mzgvgcl5na3k6f
2 Nov 23
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
7:10am
8-K
8z6a2e 5b
7 Aug 23
Corporate Presentation August 2023
4:24pm
8-K
wp9qp1
7 Aug 23
Cara Therapeutics Reports Second Quarter 2023 Financial Results
4:10pm
8-K
04g7p
3 Aug 23
Cara Therapeutics Appoints Helen M. Boudreau to
7:06am
8-K
67lz ul7ygu
2 Jun 23
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
le498hhdpw2
15 May 23
Corporate Presentation May 2023
4:21pm
8-K
geg95todjv4on798g7vo
15 May 23
Cara Therapeutics Reports First Quarter 2023 Financial Results
4:10pm
8-K
vn0yaq0eej w0
23 Mar 23
Corporate Presentation March 2023
5:04pm
8-K
v0bwwynm
10 Mar 23
Regulation FD Disclosure
5:03pm